Targeting tumor cell resistance to apoptosis induction with antisense oligonucleotides: Progress and therapeutic potential

Drug Resistance Updates

Volumn 4, Issue 1, 2001, Pages 9-15

  Olie, Robet A ^a   Zangemeister Wittke, Uwe ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ARABINOSIDE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOSINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PACLITAXEL; PROTEIN BCL 2; PROTEIN BCL X; SURVIVIN;

APOPTOSIS; CANCER THERAPY; CARCINOGENESIS; GENE OVEREXPRESSION; GENETIC DISORDER; HUMAN; MOLECULAR GENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY; SURVIVAL RATE; TUMOR RESISTANCE;

EID: 0035059838     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.2001.0181     Document Type: Review

References (57)

1. L mediate tumor cell resistance to chemotherapy
2. Dendritic cells in cancer immunotherapy
3. Apoptosis in cancer therapy: Crossing the threshold
4. A matter of life and cell death
5. The bcl-2 protein family: Arbiters of cell survival
6. Death receptors: Signaling and modulation
7. Mitochondria and apoptosis
8. Molecular thanatopsis: A discourse on the Bcl-2 family and a cell death
9. Cytochrome c and dATP-dependent formation of apaf-I/caspase-9 complex initiates an apoptotic protease cascade
10. Bid, a bcl-2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors
11. Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis
12. Prevention of apoptosis by bcl-2: Release of cytochrome c from mitochondria blocked
13. Mechanisms of drug resistance
14. Apoptosis and the dilemma of cancer chemotherapy
15. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene
16. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC)
17. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-I) death-inducing signaling complex
18. Inhibition of death receptor signals by cellular FLIP
19. Melanoma cell expression of Fas (Apo-I/CD95) ligand: Implications for tumor immune escape
20. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer
21. Colon carcinoma cells use different mechanisms to escape CD-95-mediated apoptosis
22. Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis
23. Inhibition of death receptor signaling by FLICE-inhibitory protein as a mechanism for immune escape of tumors
24. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein
25. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), bax, caspases, and anticancer drugs
26. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma
27. Control of apoptosis and mitotic spindle checkpoint by survivin
28. Molecular basis of spontaneous regression of neuroblastoma: Role of neurotrophic signals and genetic abnormalities
29. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer
30. A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognostic marker in non-small cell lung cancers
31. Specific regulation of gene expression by antisense, sense and antigene nucleic acids
32. Basic principles of antisense therapeutics
33. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix
34. Effects of synthetic oligonucleotides on human complement and coagulation
35. Antisense oligonucleotides
36. Mixed-backbone oligonucleotides as second-generation antisense agents with reduced phosphorothioate-related side effects
37. Bcl-2 antisense therapy in patients with non-Hodgkin lymphoma
38. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice
39. Eradication of human non-Hodgkin's lymphoma in SCID mice by bcl-2 antisense oligonucleotides combined with low-dose cyclophosphamide
40. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin
41. Chemosensitisation of malignant melanoma by bcl-2 antisense therapy
42. Liposomal bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins
43. Chemosensitisation and delayed androgen-independent recurrence of prostate cancer with the use of antisense bcl-2 oligodeoxynucleotides
44. Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small cell lung cancer cell lines
45. Role for Bcl-x(L) in delayed eosinophil apoptosis mediated by granulocyte-macrophage colony-stimulating factor and interleukin-5
46. The role of antiapoptotic bcl-2 family members in endothelial apoptosis elucidated with antisense oligonucleotides
47. Induction of apoptosis in lung cancer cells following bcl-xL antisense treatment
48. bcl-xL antisense treatment induces apoptosis in breast carcinoma cells
49. Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by bcl-x but not bcl-2
50. Bcl-2 and Bcl-xL can differentially block chemotherapy-induced cell death
51. Isolation and characterization of an apoptosis-resistant variant of human leukemia HL-60 cells that has switched expression from Bcl-2 to Bcl-xL
52. Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense bcl-xL and antisense bcl-2 oligonucleotides plus taxol after castration in the Shionogi tumor model
53. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells
54. Metabolic inhibitors sensitize for CD95 (APO-I/Fas)-induced apoptosis by downregulating Fas-associated death domain-like interleukin I-converting enzyme inhibitory protein expression
55. Cisplatin (CDDP) sensitizes human osteosarcoma cell to Fas/CD95-mediated apoptosis by downregulating FLIP-L expression
56. From bench to clinic with apoptosis-based therapeutic agents